Moving two candidates through clinical development
DF-003 inhibits ALPK1 and is being advanced toward a pivotal ROSAH syndrome trial. DF-006 activates innate immunity in the liver and continues clinical development for hepatitis B.
From target discovery to drug design
IDInVivo+ identifies and validates targets in living systems, while MedChem5 develops drug candidates. The Shanghai and Albany team will expand research and regulatory work across its development programs.
Where the funding goes
- DF-003 clinical development
- DF-006 hepatitis B studies
- Research and regulatory activities